Citations

Showing 10 of 108119 citations.

Shotgun Immunoproteomics for Identification of Nonhuman Leukocyte Antigens Associated With Cellular Dysfunction in Heart Transplant Rejection
Gates, Katherine V., Panicker, Anjali J., Biendarra-Tiegs, Sherri M., Vetr, Nikolai G., Higuita, Manuela Lopera, Nelson, Timothy J., Pereira, Naveen L., Griffiths, Leigh G., Gates, Katherine V. , Panicker, Anjali J. , Lopera Higuita, Manuela, Biendarra-Tiegs, Sherri M., Vetr, Nikolai G., Higuita, Manuela Lopera, Nelson, Timothy J., Pereira, Naveen L., Griffiths, Leigh G.

Mayo Clinic

Transplantation | December 19, 2021 | Volume: 106 | Issue: 7 | Pages: 1376-1389

10.1097/tp.0000000000004012 | PMID 34923540 Get It

Background. The International Society for Heart and Lung Transplant consensus panel notes that too little data exist regarding the role of non-HLA in allograft rejection. We developed a novel shotgun immunoproteomic approach to determine the identities and potential roles non-HLA play in antibody-mediated rejection (AMR) in heart transplant recipients. Methods. Serum was collected longitudinally from heart transplant recipients experiencing AMR in the absence of donor-specific anti-HLA antibodies (n = 6) and matched no rejection controls (n = 7). Antidonor heart affinity chromatography columns were formed by recipient immunoglobulin G immobilization at transplantation, acute rejection, and chronic postrejection time points. Affinity chromatography columns were used to capture antigens from individual patient’s donor heart biopsies collected at transplantation. Captured proteins were subjected to quantitative proteomic analysis and the longitudinal response was calculated. Results. Overlap in antigen-specific response between AMR and non-AMR patients was only 8.3%. In AMR patients, a total of 155 non-HLAs were identified, with responses toward 43 high prevalence antigens found in ≥50% of patients. Immunofluorescence staining for representative high prevalence antigens demonstrated that their abundance increased at acute rejection, correlating with their respective non-HLA antibody response. Physiological changes in cardiomyocyte and endothelial cell function, following in vitro culture with patient immunoglobulin G, correlated with response toward several high prevalence antigens. Conclusions. This work demonstrates a novel high-throughput strategy to identify clinically relevant non-HLA from donor endomyocardial biopsy. Such a technique has the potential to improve understanding of longitudinal timing of antigen-specific responses and their cause and effect relationship in graft rejection.
Equity or Equality? Which Approach Brings More Satisfaction in a Kidney-Exchange Chain?
Hosseinzadeh, Arian, Najafi, Mehdi , Cheungpasitporn, Wisit , Fathi, Mahdi , Fathi, Mahdi , Cheungpasitporn, Wisit , Thongprayoon, Charat

Mayo Clinic

Journal of Personalized Medicine | December 19, 2021 | Volume: 11 | Issue: 12 | Pages: 1383

10.3390/jpm11121383 | PMID 34945855 Get It

In United States (U.S.), government-funded organizations, such as NLDAC, reimburse travel and subsistence expenses incurred during living-organ donation process. However, in Iran, there is a non-governmental organization called Iranian Kidney Foundation (IKF) that funds the direct and indirect costs of donors through charitable donations and contributions from participants in the exchange program. In this article, for countries outside the U.S. that currently use an equality approach, we propose a potential new compensation-apportionment approach (equitable approach) for kidney-exchange chains and compare it with the currently available system (equality approach) in terms of the apportionment of compensation in a kidney-exchange chain to cover the expenses incurred by the initiating living donor of the chain in the act of donation. To this end, we propose a mechanism to apportion compensation among all participating pairs based on the equity approach by utilizing a prediction model to calculate the probability of graft survival in each transplant operation. These probabilities are then used to define the utility of any transplantation, considering the quality of each pair’s donated and received kidney in the chain. Afterward, the corresponding cost is apportioned by a mechanism based on the normalized differences between the utility of donated and received kidneys for each incompatible pair of the chain. In summary, we demonstrate that by utilizing the equitable approach, there is more fairness and equity in the allocation of resources in organ-procurement systems, which results in more satisfaction among incompatible pairs. Additional future prospective studies are needed to assess this proposed equitable approach for kidney-exchange chains in countries outside the U.S., such as Iran, that currently use an equality approach.
Polyurethane Foam Incorporated with Nanosized Copper-Based Metal-Organic Framework: Its Antibacterial Properties and Biocompatibility
Gwon, Kihak , Nam, Yunhee, Lee, Su Jung , Ngoc, Tran Minh , Yoo, Hyojong , Gwon, Kihak , Yoo, Hyojong , Lee, Do Nam

Mayo Clinic

International Journal of Molecular Sciences | December 19, 2021 | Volume: 22 | Issue: 24 | Pages: 13622

10.3390/ijms222413622 | PMID 34948419 Get It

Polyurethane foams (PUFs) have attracted attention as biomaterials because of their low adhesion to the wound area and suitability as biodegradable or bioactive materials. The composition of the building blocks for PUFs can be controlled with additives, which provide excellent anti-drug resistance and biocompatibility. Herein, nanosized Cu-BTC (copper(II)-benzene-1,3,5-tricarboxylate) was incorporated into a PUF via the crosslinking reaction of castor oil and chitosan with toluene-2,4-diisocyanate, to enhance therapeutic efficiency through the modification of the surface of PUF. The physical and thermal properties of the nanosized Cu-BTC-incorporated PUF (PUF@Cu-BTC), e.g., swelling ratio, phase transition, thermal gravity loss, and cell morphology, were compared with those of the control PUF. The bactericidal activities of PUF@Cu-BTC and control PUF were evaluated against Pseudomonas aeruginosa, Klebsiella pneumoniae, and methicillin-resistant Staphylococcus aureus. PUF@Cu-BTC exhibited selective and significant antibacterial activity toward the tested bacteria and lower cytotoxicity for mouse embryonic fibroblasts compared with the control PUF at a dose of 2 mg mL−1. The Cu(II) ions release test showed that PUF@Cu-BTC was stable in phosphate buffered saline (PBS) for 24 h. The selective bactericidal activity and low cytotoxicity of PUF@Cu-BTC ensure it is a candidate for therapeutic applications for the drug delivery, treatment of skin disease, and wound healing.
Single-Dose P2 X4R Single-Chain Fragment Variable Antibody Permanently Reverses Chronic Pain in Male Mice
Westlund, Karin N. , Montera, Marena A., Goins, Aleyah E. , Alles, Sascha R.A. , Suri, Nikita, McIlwrath, Sabrina L., Bartel, Robyn , Durvasula, Ravi , Kunamneni, Adinarayana , Durvasula, Ravi V, Westlund, Karin N , Alles, Sascha Ra , Suri, Nikita

Mayo Clinic

International Journal of Molecular Sciences | December 19, 2021 | Volume: 22 | Issue: 24 | Pages: 13612

10.3390/ijms222413612 | PMID 34948407 Get It

Non-opioid single-chain variable fragment (scFv) small antibodies were generated as pain-reducing block of P2X4R receptor (P2X4R). A panel of scFvs targeting an extracellular peptide sequence of P2X4R was generated followed by cell-free ribosome display for recombinant antibody selection. After three rounds of bio-panning, a panel of recombinant antibodies was isolated and characterized by ELISA, cross-reactivity analysis, and immunoblotting/immunostaining. Generated scFv antibodies feature binding activity similar to monoclonal antibodies but with stronger affinity and increased tissue penetrability due to their ~30% smaller size. Two anti-P2X4R scFv clones (95, 12) with high specificity and affinity binding were selected for in vivo testing in male and female mice with trigeminal nerve chronic neuropathic pain (FRICT-ION model) persisting for several months in untreated BALBc mice. A single dose of P2X4R scFv (4 mg/kg, i.p.) successfully, completely, and permanently reversed chronic neuropathic pain-like measures in male mice only, providing retention of baseline behaviors indefinitely. Untreated mice retained hypersensitivity, and developed anxiety- and depression-like behaviors within 5 weeks. In vitro P2X4R scFv 95 treatment significantly increased the rheobase of larger-diameter (>25 µm) trigeminal ganglia (TG) neurons from FRICT-ION mice compared to controls. The data support use of engineered scFv antibodies as non-opioid biotherapeutic interventions for chronic pain.
Inpatient pediatric chaplain service utilization among children with chronic, non-cancer diseases
Case, Hannah F., Benning, Tyler J. , Lovig, Zachary, Girard, Jeramy, Thorvilson, Megan J. , Homme, Jason H. , Case, Hannah , Benning, Tyler, Thorvilson, Megan, Fischer, Philip R. , Homme, Jason

Mayo Clinic

Journal of Health Care Chaplaincy | December 19, 2021 | Volume: 28 | Issue: 4 | Pages: 578-590

10.1080/08854726.2021.2015054 | PMID 34923924 Get It

Clinical Significance of Staphylococcus aureus in a Single Positive Blood Culture Bottle
Go, John Raymond , Campioli, Cristina Corsini , Sohail, M. Rizwan , Palraj, Raj , Baddour, Larry M. , Saleh, Omar Abu , Challener, Douglas , Corsini Campioli, Cristina , Sohail, M Rizwan , Palraj, Raj , Baddour, Larry , Abu Saleh, Omar , Go, J Raymond , Challener, Douglas W.

Mayo Clinic

Open Forum Infectious Diseases | December 18, 2021 | Volume: 9 | Issue: 2 | Pages: No page available

10.1093/ofid/ofab642 | PMID 35071685 Get It

Abstract Clinical significance of a single positive blood culture bottle (SPBCB) with Staphylococcus aureus is unclear. We aimed to assess the significance of an SPBCB by looking at the associated outcomes. We performed a retrospective, multicenter study of patients with an SPBCB with S aureus using data collected from both electronic health records and the clinical microbiology laboratory. Overall, 534 patients with S aureus bacteremia were identified and 118 (22.1%) had an SPBCB. Among cases with an SPBCB, 106 (89.8%) were classified as clinically significant whereas 12 (10.2%) were considered contaminated or of unclear significance. A majority (92.4%) of patients received antibiotic therapy, but patients with clinically significant bacteremia were treated with longer courses (25.9 vs 5.7 days, P < .001). Significant differences in both frequency of echocardiography (65.1% vs 84.6%, P < .001) and infective endocarditis diagnosis (3.8% vs 14.2%, P = .002) were seen in those with an SPBCB compared to those with multiple positive bottles. A longer hospital length of stay and higher 90-day, 6-month, and 1-year mortality rates were seen in patients with multiple positive blood culture bottles. An SPBCB with S aureus was common among our patients. While this syndrome has a more favorable prognosis as compared to those with multiple positive blood cultures, clinicians should remain concerned as it portends a risk of infective endocarditis and mortality.
Ninety‐day mortality and clinical outcomes of patients with solid tumours and COVID‐19 infection during the first pandemic outbreak in Catalonia, Spain: A multicentre retrospective study
Tapia, José Carlos , Gavira, Javier , López, Assumpció, Llobera, Laia, Pallisé, Ona , Marsal, Irene, Cochs, Alba, Ponce, Oscar J. , Riudavets, Mariona , Barnadas, Agustí , Barnadas, Agusti , Majem, Margarita , Ponce, Oscar Josue , Gich, Ignasi

Mayo Clinic

International Journal of Cancer | December 18, 2021 | Volume: 150 | Issue: 8 | Pages: 1310-1317

10.1002/ijc.33909 | PMID 34921732 Get It

AbstractTo describe the clinical outcomes and risk factors for 90‐day mortality in patients with solid tumours (ST) and coronavirus disease 2019 (COVID‐19) during the first outbreak in Catalonia. This is a multicentre retrospective study including adults with ST and COVID‐19 confirmed by real time reverse transcription polymerase chain reaction between 13 March and 30 April 2020. Clinical and survival data were collected. Follow‐up ended on 30 July 2020. Multivariate and survival analysis were performed. A hundred and fifteen patients were included. In all, 42.6% had advanced disease and were receiving anticancer treatment; 7% were admitted to the ICU and 22.6% died during hospitalisation. Thirty‐day mortality was 27.8%, which increased to 33.9% at 90 days. Ninety‐day mortality was associated with current smoker status (hazard ratio [HR]: 2.91, 95% CI [confidence interval]: 1.03‐8.33, P = .044), baseline ECOG‐PS 2 to 3 (HR: 3.88, 95% CI: 1.77‐8.46, P < .001]), dyspnoea (HR: 3.02, 95% CI: 1.31‐6.96, P = .009), a respiratory rate ≥ 24 (HR: 2.24, 95% CI: 1.02‐4.92, P = .046) and sepsis (HR: 3.97, 95% CI: 1.78‐8.88, P < .001). Of the 76 survivors, 73.6% had a follow‐up visit. Of those, 33.9% had their cancer controlled and 23.2% had progressed. Thirty‐five survivors were receiving anticancer treatment before COVID‐19 diagnosis though 14 had to discontinue the treatment. Eight survivors without previous anticancer therapy started therapy. The median time to start anticancer therapy after COVID‐19 was 45 days (interquartile range: 28‐61). In conclusion, 90‐day mortality in patients with ST and COVID‐19 was 33.9%; current smoker status, poor ECOG‐PS, dyspnoea, respiratory rate ≥24 and sepsis were independent risk factors for mortality; and survivors did not restart their anticancer treatment until 1.5 months after COVID‐19 diagnosis.
Evaluation of soluble fibrin monomer complex in patients in SARS‐CoV‐2 COVID‐19 infection‐associated coagulopathy
Sridharan, Meera , Navitskas, Serena D., Kock, Elizabeth M., Heikal, Nahla, Chen, Dong , Pruthi, Rajiv K. , D Navitskas, Serena, M Kock, Elizabeth, E Houghton, Damon, M Heikal, Nahla, K Pruthi, Rajiv, Chen, Dong , Sridharan, Meera , Houghton, Damon E.

Mayo Clinic

European Journal of Haematology | December 18, 2021 | Volume: 108 | Issue: 4 | Pages: 319-326

10.1111/ejh.13738 | PMID 34921683 Get It

AbstractHospitalized patients with COVID‐19 infection frequently have coagulopathy resembling disseminated intravascular coagulation (DIC). An elevation of D‐dimer level is associated with a poor prognosis; however, the role of other fibrin degradation products, such as soluble fibrin monomers (SFMC), is not known.The objective of the study was to investigate the frequency and prognostic role of elevated SFMC in patients with COVID‐19. In this retrospective cohort study, patients hospitalized between April 1, 2020 and December 14, 2020 at Mayo Clinic with COVID‐19 infection who underwent DIC panel testing were identified. Results of laboratory tests and outcomes (thrombosis and death) within 40 days of testing were obtained via medical record review.Of 108 patients, D‐dimer was elevated in 82 (75.9%) patients. Of those with elevated D‐dimer, SFMC was elevated in 19/82 (23%) patients. There were 16 thrombotic events and 16 deaths during the 40‐day follow‐up. The incidence of overt‐DIC was 4.6%. In univariate analysis, D‐dimer ≥5 x highest upper limit normal (ULN) and elevated SFMC were each associated with higher 40‐day mortality. However, when used in combination with D‐dimer ≥5 x highest ULN, an elevated SFMC provided no further mortality predictive value.Compared to 75.9% of patients with elevated D‐dimers, of those tested, only 23% had elevated SFMC. These results support the hypothesis that elevated D‐dimer in COVID‐19 infection is a direct consequence of endothelial damage and not overt‐DIC.
Topography of the deep temporal arteries and implications for performing safe aesthetic injections
Nikolis, Andreas , Enright, Kaitlyn M. , Troupis, Theodore , Koutsilieris, Michael, Stratigos, Alexander , Rigopoulos, Dimitrios , Cotofana, Sebastian , Cotofana, Sebastian

Mayo Clinic

Journal of Cosmetic Dermatology | December 18, 2021 | Volume: 21 | Issue: 2 | Pages: 608-614

10.1111/jocd.14672 | PMID 34921494 Get It

AbstractBackgroundSeveral studies have started investigating the safety of temporal rejuvenation using soft tissue fillers. However, as the temporal region is highly vascularized, adverse events due to intravascular injection are of primary concern. The scarcity of treatment guidelines to date have focused primarily on avoiding the superficial and middle temporal arteries. The aim of the present anatomical study was to describe the topography of the deep temporal arteries (DTAs) with reference to superficial landmarks, to aid clinicians who perform temporal injections.MethodsThe tissue layers of eight fresh‐frozen cephalic cadavers were dissected and assessed, bilaterally in the temporal region (N = 16). Distance (D) of the anterior (D1 and D3) and posterior (D2 and D4) arteries was measured from (i) the zygomaticofrontal suture line at the lateral orbital rim (D1 and D2) and (ii) the junction of the superior border of the zygomatic arch and lateral orbital rim (D3 and D4). The distance between the anterior and posterior DTAs was also recorded, at the two regions (D5).ResultsBifurcations of the DTAs were observed in 18.75% (3/16) and 12.5% (2/16) of cases, for the anterior and posterior branches, respectively. On average [mean (standard deviation)], D1 (anterior DTA to the zygomaticofrontal suture line at the lateral orbital rim) = 1.56 cm (0.59); D2 (posterior DTA to the zygomaticofrontal suture line at the lateral orbital rim) = 2.98 cm (0.70); D3 (anterior DTA to the junction of the superior border of the zygomatic arch and lateral orbital rim) = 1.14 cm (0.63); D4 (posterior DTA to the junction of the superior border of the zygomatic arch and lateral orbital rim) = 2.37 cm (0.62); and D5 (distance between the anterior and posterior DTAs) = 1.54 cm (0.68).ConclusionTo help avoid vascular adverse events while performing temporal injections, aesthetic clinicians should be conscientious of safety implications related to the anatomical location of the DTAs and their ramifications.
Personalizing Diabetes Management in Liver Transplant Recipients: The New Era for Optimizing Risk Management
Richardson, Brooks , Khan, Mohammad Qasim , Brown, Sara , Watt, Kymberly D. , Izzy, Manhal , Khan, Mohammad Qasim

Mayo Clinic

Hepatology Communications | December 18, 2021 | Volume: 6 | Issue: 6 | Pages: 1250-1261

10.1002/hep4.1876 | PMID 34921530 Get It

Post‐transplant diabetes mellitus (PTDM) is a significant contributor to morbidity and mortality in liver transplant recipients (LTRs). With concurrent comorbidities and use of various immunosuppression medications, identifying a safe and personalized regimen for management of PTDM is needed. There are many comorbidities associated with the post‐transplant course including chronic kidney disease, cardiovascular disease, allograft steatosis, obesity, and de novo malignancy. Emerging data suggest that available diabetes medications may carry beneficial or, in some cases, harmful effects in the setting of these co‐existing conditions. Sodium‐glucose co‐transporter 2 inhibitors and glucagon‐like peptide 1 receptor agonists have shown the most promising beneficial results. Although there is a deficiency of LTR‐specific data, they appear to be generally safe. Effects of other medications are varied. Metformin may reduce the risk of malignancy. Pioglitazone may be harmful in patients combatting obesity or heart failure. Insulin may exacerbate obesity and increase the risk of developing malignancy. This review thoroughly discusses the roles of these extra‐glycemic effects and safety considerations in LTRs. Through weighing the risks and benefits, we conclude that alternatives to insulin should be strongly considered, when feasible, for personalized long‐term management based on risk factors and co‐morbidities.